CHPA “approvable”letter comments
This article was originally published in The Tan Sheet
Executive Summary
FDA "should clearly define specific deficiencies" in an application in a complete response letter, the Consumer Healthcare Products Association says in Oct. 18 comments on the agency's proposed rule to discontinue use of "approvable" and "not approvable" letters. Defining deficiencies "would avoid presentation of new issues at a later date after a complete response letter has been issued, and minimize the potential for cycles of complete response letters," CHPA states. The association "supports" FDA's proposal to use complete response letters once the review cycle is complete but an application is not ready for approval. The proposed reg was published in July (1"The Tan Sheet" July 26, 2004, p. 11)...
You may also be interested in...
“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs
The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.